Healthcare is one of the few sectors where competitive advantages compound over decades. Patent portfolios, FDA approvals, hospital networks, and switching costs create barriers that take years (sometimes decades) to replicate. That makes healthcare stocks natural hunting ground for moat investors.
We screened every healthcare company in Moatifi's database for moat scores of 8 or higher. Seven companies stood out across different subsectors, from pharma giants to medical device makers to the largest hospital operator in the country.
Here is what the data shows for each one.
1. UnitedHealth Group (UNH): Moat Score 8/10
UnitedHealth is not just an insurance company. It is the largest healthcare organization in the United States, covering 53+ million members through UnitedHealthcare and operating Optum, which has become a healthcare services empire unto itself.
Why the moat is wide:
- Network effects: More members means more negotiating power with hospitals and doctors, which means lower costs, which attracts more members. This flywheel has been spinning for 20+ years.
- Switching costs: Employers rarely switch health plans. The administrative complexity of moving thousands of employees to a new insurer creates enormous inertia.
- Data advantage: Optum processes billions of healthcare claims annually. That data feeds AI-powered tools for cost prediction, fraud detection, and care management that smaller insurers cannot match.
UnitedHealth scores 9/10 on AI survival in Moatifi's analysis. The company is already deploying machine learning across claims processing, clinical decision support, and population health management. AI makes UNH's existing advantages stronger, not weaker.
Key risk: Regulatory. Medicare Advantage reimbursement rates are set by the government. Policy changes could compress margins.
2. Eli Lilly (LLY): Moat Score 8/10
Eli Lilly has become the most valuable pharmaceutical company in the world, driven largely by its GLP-1 drugs (Mounjaro and Zepbound) for diabetes and obesity. But the moat runs deeper than one drug class.
Why the moat is wide:
- Intangible assets: Lilly's patent portfolio on GLP-1 molecules extends well into the 2030s. Generic competition is years away.
- R&D pipeline: Over 50 molecules in clinical development across neuroscience, oncology, and immunology. The obesity franchise alone could generate $50+ billion in peak annual sales.
- Manufacturing scale: GLP-1 drugs require complex biologic manufacturing. Lilly has invested $18+ billion in new manufacturing capacity. Competitors cannot ramp up quickly.
The obesity drug market did not exist at scale three years ago. Lilly created the category alongside Novo Nordisk and now has supply constraints (demand exceeds production capacity). That is the kind of problem moat investors love.
Key risk: Valuation. LLY trades at a premium that prices in nearly flawless execution. Any pipeline setback could trigger a sharp correction.
3. Thermo Fisher Scientific (TMO): Moat Score 9/10
Thermo Fisher is the picks-and-shovels play for the entire life sciences industry. Every pharmaceutical company, biotech startup, hospital, and research university buys equipment, reagents, and services from Thermo Fisher.
Why the moat is wide:
- Switching costs (9/10): Labs standardize on Thermo Fisher instruments and consumables. Switching means revalidating protocols, retraining staff, and risking data compatibility. Nobody does that voluntarily.
- Brand power (9/10): The company operates under trusted brands including Thermo Scientific, Applied Biosystems, Fisher Scientific, and Invitrogen. These names carry weight in regulated environments where reliability is non-negotiable.
- Scale: $45+ billion in revenue. The breadth of the product catalog (over 700,000 products) means customers consolidate purchasing with TMO for efficiency.
Thermo Fisher scores an exceptional 9.5/10 on AI survival. The company's instruments generate data that feeds AI-driven drug discovery, making TMO more essential as pharma increasingly relies on computational approaches.
Run TMO through Moatifi's full analysis to see the complete breakdown.
4. Stryker Corporation (SYK): Moat Score 8/10
Stryker makes surgical equipment, orthopedic implants, and medical devices. If you have ever had a hip or knee replacement, there is a good chance Stryker hardware is inside you.
Why the moat is wide:
- Switching costs: Surgeons train for years on specific implant systems. A hospital does not switch from Stryker knee implants to a competitor's because the surgeon knows Stryker's instrumentation, sizing, and surgical technique by muscle memory.
- Brand power (9/10): In orthopedics, brand reputation correlates directly with patient outcomes data. Stryker's Mako robotic surgery system has become the standard in joint replacement, with 20,000+ procedures per quarter.
- Regulatory barriers: Every new medical device requires FDA clearance or approval, clinical trials, and years of post-market surveillance. This process protects incumbents like Stryker from fast-moving startups.
Medical devices is one of the stickiest businesses in healthcare. Once a hospital installs a Stryker Mako robot ($1.5M+ per unit), the ongoing revenue from implants and instruments flows for the life of that installation.
Key risk: Hospital capital spending cycles. During economic downturns, hospitals delay equipment purchases (though the replacement demand always catches up).
5. Vertex Pharmaceuticals (VRTX): Moat Score 9/10
Vertex has a near-monopoly in cystic fibrosis (CF) treatment. Trikafta, the company's flagship drug, is taken by approximately 90% of CF patients in the developed world.
Why the moat is wide:
- Switching costs (9/10): CF patients who respond to Trikafta have no incentive to switch. The drug transformed a fatal disease into a manageable chronic condition. Patient and physician loyalty is extreme.
- Patent fortress: Vertex has layered patents protecting its CF franchise through the early 2030s, with next-generation therapies (vanzacaftor triple) extending protection further.
- Pipeline diversification: Vertex is expanding beyond CF into pain (non-opioid VX-548), kidney disease, and gene editing (Casgevy for sickle cell disease). Each new franchise reduces dependence on CF.
A company that treats 90% of a patient population for a genetic disease has one of the deepest moats in all of biotech. Competitors have tried for over a decade to develop rival CF treatments and failed. The biology is that hard.
Check Moatifi's breakdown of Vertex for the full competitive analysis.
Key risk: CF patient population is finite (approximately 83,000 in developed markets). Growth depends on pipeline execution in new therapeutic areas.
6. IDEXX Laboratories (IDXX): Moat Score 8/10
IDEXX dominates veterinary diagnostics. If your dog gets a blood test at the vet, the machine that runs it is almost certainly made by IDEXX.
Why the moat is wide:
- Switching costs (9/10): Veterinary practices install IDEXX analyzers and build their entire workflow around the platform (software, reference lab integration, patient records). Switching means disrupting everything.
- Market dominance: IDEXX holds roughly 50%+ of the in-clinic veterinary diagnostics market globally. The next largest competitor has less than half that share.
- Recurring revenue: The analyzers are placed at low or no cost; revenue comes from consumables (test cartridges, reagents). This razors-and-blades model generates predictable, high-margin cash flow.
Pet healthcare spending has grown every single year for the past two decades, regardless of economic conditions. Americans spent $38 billion on veterinary care in 2025. That number only goes up as pet ownership increases and owners spend more per animal.
Key risk: Valuation premium. IDXX trades at a rich multiple because the growth is so consistent. Any hiccup in vet visit trends could compress the stock.
7. HCA Healthcare (HCA): Moat Score 8/10
HCA is the largest for-profit hospital operator in the United States, running 186 hospitals and 2,400+ care sites across 20 states and the UK.
Why the moat is wide:
- Cost advantages (8/10): Scale matters in healthcare operations. HCA negotiates better rates on supplies, staffing, and technology than smaller hospital systems. Its data analytics platform identifies operational efficiencies across all 186 facilities.
- Switching costs: Patients build relationships with their local hospital and specialists. Physicians build their practices around HCA facilities. Moving an established hospital network is essentially impossible.
- Regulatory barriers: Building a new hospital requires a Certificate of Need in many states, limiting competition. HCA's existing footprint in high-growth markets (Texas, Florida) is nearly irreplaceable.
HCA scores 9/10 on AI survival. The company is deploying AI for clinical decision support, staffing optimization, and revenue cycle management. Larger hospital systems benefit disproportionately from AI because they have more data to train models on.
Key risk: Labor costs. Nurse and physician shortages drive up wages. Government reimbursement does not always keep pace.
How These 7 Compare
| Stock | Moat Score | AI Survival | Key Moat Source | Subsector |
|---|---|---|---|---|
| UNH | 8/10 | 9.0 | Network effects + data | Insurance/services |
| LLY | 8/10 | 7.0 | Patents + manufacturing | Pharma |
| TMO | 9/10 | 9.5 | Switching costs + scale | Life sciences tools |
| SYK | 8/10 | 8.0 | Surgeon lock-in + brand | Medical devices |
| VRTX | 9/10 | 8.0 | 90% CF market share | Biotech |
| IDXX | 8/10 | 8.5 | Platform lock-in | Veterinary diagnostics |
| HCA | 8/10 | 9.0 | Scale + regulatory | Hospitals |
Run any of these through Moatifi's free screener to see the full analysis, including valuation scores and fair value estimates.
Why Healthcare Moats Matter in 2026
With Warren Buffett sitting on a $344 billion cash pile and the broader market trading at elevated valuations, defensive quality matters. Healthcare stocks have three advantages in uncertain markets:
- Demand is inelastic. People do not stop taking medication or visiting hospitals because the stock market drops. Revenue stability is built into the business model.
- Pricing power persists. Patented drugs, proprietary devices, and essential services allow healthcare companies to raise prices in ways that commodity businesses cannot.
- AI is additive, not disruptive. Unlike sectors where AI threatens existing business models (see our piece on stocks losing their moats), healthcare companies use AI to enhance their existing advantages rather than replace them.
The best healthcare moat stocks combine the defensive qualities of the sector with genuine competitive advantages that grow stronger over time. These 7 companies score highest on that combination in our database.
For more on building a moat-focused portfolio, read our guides on economic moat investing strategy, recession-proof stocks with wide moats, and how to find undervalued stocks using moat analysis.